Want to see HK:2617 full AI Analyst Report?
Top Page
TransThera Sciences (Nanjing). Inc.
(2617)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$9.50
▼(-10.88% Downside)
Action:Reiterated
Date:07/03/26
The score is held down primarily by minimal/zero recent revenue, large ongoing losses, and substantial negative operating/free cash flow, which imply continued reliance on external funding. Technicals reinforce the risk with a pronounced downtrend and weak momentum. The key offset is a conservatively financed balance sheet with very low leverage, which reduces near-term solvency pressure despite ongoing burn.
Positive Factors
Very low leverage
Minimal leverage reduces refinancing and interest-rate exposure, giving the company greater financial flexibility than a heavily indebted biotech. This can help preserve strategic options while clinical programs advance, although the benefit depends on controlling ongoing cash consumption.
Negative Factors
Effectively pre-revenue
The absence of meaningful recent revenue shows that the business has not yet established a commercial revenue base to support operations. This leaves financial progress dependent on clinical advancement and eventual commercialization rather than recurring operating receipts over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal leverage reduces refinancing and interest-rate exposure, giving the company greater financial flexibility than a heavily indebted biotech. This can help preserve strategic options while clinical programs advance, although the benefit depends on controlling ongoing cash consumption.
Read all positive factors
TransThera Sciences (Nanjing). Inc. (2617) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.94B
Dividend YieldN/A
Average Volume (3M)7.78M
Price to Earnings (P/E)―
Beta (1Y)3.20
Revenue GrowthN/A
EPS Growth-13.84%
CountryHK
Employees132
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding312,687,680
10 Day Avg. Volume3,771,800
30 Day Avg. Volume7,778,172
Financial Highlights & Ratios
PEG Ratio-13.39
Price to Book (P/B)96.58
Price to Sales (P/S)0.00
P/FCF Ratio-158.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TransThera Sciences (Nanjing). Inc. Business Overview & Revenue Model
Company Description
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420),...
TransThera Sciences (Nanjing). Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.97M | 0.00 | 0.00 | 1.18M | 124.00K | 61.76M |
| Gross Profit | 30.68M | 0.00 | 0.00 | 1.18M | 124.00K | 0.00 |
| EBITDA | -267.60M | -290.82M | -267.97M | -416.80M | -346.90K | -39.27M |
| Net Income | -268.29M | -295.96M | -274.61M | -344.12M | -250.04M | -80.72M |
Balance Sheet | ||||||
| Total Assets | 987.24M | 545.91M | 629.60M | 887.09M | 1.35B | 344.94M |
| Cash, Cash Equivalents and Short-Term Investments | 925.22M | 489.14M | 572.53M | 838.17M | 1.11B | 279.34M |
| Total Debt | 5.61M | 1.65M | 4.37M | 4.81M | 3.04M | 490.74M |
| Total Liabilities | 109.26M | 129.53M | 104.57M | 103.91M | 111.04M | 578.87M |
| Stockholders Equity | 877.99M | 416.38M | 525.03M | 783.18M | 1.24B | -233.94M |
Cash Flow | ||||||
| Free Cash Flow | -144.55M | -253.68M | -271.95M | -331.12M | -244.00M | -76.61M |
| Operating Cash Flow | -144.47M | -253.51M | -271.18M | -319.33M | -241.94M | -66.68M |
| Investing Cash Flow | 108.03M | -68.00M | 348.42M | -186.94M | 26.98M | -195.84M |
| Financing Cash Flow | 1.55M | 169.00M | -4.87M | 15.76M | 240.45M | 311.48M |
TransThera Sciences (Nanjing). Inc. Technical Analysis
Neutral
10.66
Price Trends
10.25
Negative
21.89
Negative
60.37
Negative
Market Momentum
-0.43
Negative
47.27
Neutral
46.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2617, the sentiment is Neutral. The current price of 10.66 is above the 20-day moving average (MA) of 9.88, above the 50-day MA of 10.25, and below the 200-day MA of 60.37, indicating a neutral trend. The MACD of -0.43 indicates Negative momentum. The RSI at 47.27 is Neutral, neither overbought nor oversold. The STOCH value of 46.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2617.
TransThera Sciences (Nanjing). Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$62.58B | 11.05 | 128.12% | ― | 305.94% | ― | |
64 Neutral | HK$31.84B | 32.07 | 20.41% | ― | 32.63% | 8.87% | |
62 Neutral | HK$84.46B | -16.79 | -16.23% | 0.35% | 53.48% | -120.02% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$22.37B | -15.05 | -27.40% | ― | 5.38% | 16.86% | |
46 Neutral | HK$33.73B | -77.73 | -7.32% | ― | 34.83% | 58.94% | |
44 Neutral | HK$2.94B | -8.32 | -40.84% | ― | ― | -13.84% |
* General Sector Average
HK:2617
TransThera Sciences (Nanjing). Inc.
10.03
-139.87
-93.31%
HK:1548
Genscript Biotech
39.34
22.28
130.60%
HK:9688
Zai Lab Ltd
20.58
-4.78
-18.85%
HK:9995
RemeGen Co. Ltd. Class H
74.70
-29.20
-28.10%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.31
-14.79
-46.07%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
59.70
-17.90
-23.07%
TransThera Sciences (Nanjing). Inc. Corporate Events
TransThera’s Tinengotinib Secures CSCO Guideline Placement for Advanced Biliary Tract Cancers
Sep 18, 2026
TransThera Sciences has announced that its self-developed multi-target kinase inhibitor YOCHANRA (tinengotinib) has been included as a Class II, Class 2A recommendation in the 2026 Chinese Society of Clinical Oncology guidelines for the diagnosis ...
TransThera Starts Phase II Trial of Tinengotinib Combo in Resistant Prostate Cancer
Sep 18, 2026
TransThera Sciences (Nanjing), Inc., a China-based biopharma company specializing in innovative oncology drugs, is developing tinengotinib, a multi-target kinase inhibitor aimed at solid tumors such as cholangiocarcinoma and prostate cancer. With ...
TransThera Sciences Narrows Interim Loss as Revenue Emerges Amid Rising R&D Spend
Aug 26, 2026
TransThera Sciences (Nanjing), Inc. reported its unaudited interim results for the six months ended 30 June 2026, posting revenue of RMB35.46 million versus no revenue a year earlier and a gross profit of the same amount as no cost of sales was re...
TransThera Sciences Sets Board Meeting to Review Interim Results and Potential Dividend
Aug 14, 2026
TransThera Sciences (Nanjing), Inc. has scheduled a board meeting for 26 August 2026 to review and approve its unaudited consolidated interim results for the six months ended 30 June 2026. The board will also consider the declaration and payment o...
TransThera Wins First China Approval for Yochanra in Advanced Cholangiocarcinoma
Aug 6, 2026
TransThera Sciences (Nanjing) has secured conditional marketing approval in China for its Class 1 new drug Yochanra, or tinengotinib tablets, to treat adult patients with unresectable advanced or metastatic cholangiocarcinoma harboring FGFR2 fusio...
TransThera Grants Over 5.2 Million H-Share Awards and Options to Staff
Jul 24, 2026
TransThera Sciences (Nanjing), Inc. has granted a total of 2,816,900 share awards and 2,442,000 share options, representing 5,258,900 H shares, to 67 employees under its H Share Award Scheme, including allocations to directors Frank Wu and Wu Di. ...
TransThera Wins NMPA Nod for Phase II Lung Cancer Trial of TT-00973 Combo
Jul 10, 2026
TransThera Sciences (Nanjing), Inc. has received approval from China’s National Medical Products Administration to initiate a multi-center, open-label Phase II clinical trial of its novel AXL/FLT3 inhibitor TT-00973 in combination with firmo...
TransThera Completes Global Phase III Enrollment for Tinengotinib in Advanced Cholangiocarcinoma
Jul 1, 2026
TransThera Sciences has completed patient enrollment in a global multicenter, randomized Phase III trial of its lead drug tinengotinib as an oral monotherapy for advanced cholangiocarcinoma with FGFR gene aberrations that has relapsed or become re...
TransThera Wins China Nod for Phase II Trial of Novel BTK Inhibitor in Mantle Cell Lymphoma
Jul 1, 2026
TransThera Sciences (Nanjing), Inc. has received approval from China’s National Medical Products Administration to initiate a Phase II trial of its novel BTK inhibitor TT-01488 in combination with an anti-CD20 monoclonal antibody for mantle ...
TransThera Sciences to Launch Up to RMB100 Million H-Share Buyback
Jun 28, 2026
TransThera Sciences (Nanjing), Inc. has announced a plan to repurchase up to RMB100 million worth of its H shares on the open market under a general mandate granted by shareholders at the 18 June 2026 annual general meeting. The repurchase window ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.